![]()
|
|
||||||||
J Biol Chem, Vol. 273, Issue 41, 26317-26322, October 9, 1998
From the Department of Pharmacology, University of Texas
Southwestern Medical Center, Dallas, Texas 75235-9041
The parasitic protozoan Trypanosoma
brucei utilizes a conjugate of glutathione and spermidine, termed
trypanothione, in place of glutathione to maintain cellular redox
balance. The first committed step in the biosynthesis of glutathione
and thereby trypanothione, is catalyzed by The parasitic protozoa Trypanosoma brucei is the
causative agent of African sleeping sickness. T. brucei is
responsible for significant morbidity and mortality, yet the available
anti-trypanosomal drugs are limited in effectiveness by drug
resistance, by high toxicity and by their lack of action against late
stage disease (1). Major differences have been found in the utilization
of the tripeptide thiol glutathione (GSH) between the parasite and the
mammalian host. Mammals rely on GSH for protection against oxidative
injury by peroxides or free radicals and for detoxification of
xenobiotics (2). Trypanosomes maintain redox balance by synthesizing a
conjugate of glutathione and spermidine, termed trypanothione (3). The
reduced form of trypanothione is maintained by trypanothione reductase,
a homolog of mammalian glutathione reductase (4).
The first step in the biosynthesis of glutathione, and thereby
trypanothione, is catalyzed by Studies on mammalian Little is known about the active site or catalytically relevant
residues of We recently cloned T. brucei Materials
Reagents for the enzyme assay were purchased from Sigma,
Ni2+-agarose and pREP4 were purchased from Qiagen.
Mutagenesis
Site-directed mutagenesis was performed as described (37)
using an oligonucleotide (5'-ATGGTAAGCTGCAGGGCGTTGCAGCCC-3')
designed to incorporate a PstI site and to mutate
Cys-319 to Ala (Fig. 1). Mutagenesis was performed in the Bluescript
SK Expression Constructs
pTbCtag--
We previously reported the expression of pTb-GCSC319A--
The mutated fragment was cloned into the
XbaI/SacI sites of pTbCtag, described above, to
generate C-terminally tagged pTbC319A.
Expression in E. coli and Purification
wt-Tb Enzyme Assays and Kinetic Analysis
All kinetic analysis was done on purified NADH has been reported to be a competitive inhibitor of ATP for the rat
Cystamine Inhibition Studies
The time-dependent inhibitor cystamine was incubated
with wt-Tb Analysis of the Kinetic Mechanism
Data to assess the kinetic mechanism was collected for
wt-Tb The Role of Cys-319 in Cystamine Inactivation of
Trypanosoma brucei
-Glutamylcysteine
Synthetase
CHARACTERIZATION OF THE KINETIC MECHANISM AND THE ROLE OF
CYS-319 IN CYSTAMINE INACTIVATION*
and
![]()
ABSTRACT
Top
Abstract
Introduction
Procedures
Results
Discussion
References
-glutamylcysteine
synthetase (
-GCS). We have determined the kinetic mechanism for
T. brucei
-GCS. The kinetics are best described by a
rapid equilibrium random ter-reactant mechanism, in which the model
derived Kd values for the binding of
L-Glu, L-
-aminobutyrate, and ATP to free
enzyme are 2.6, 5.1, and 1.4 mM, respectively. However,
significant dependences exist between the binding of some of the
substrate pairs. The binding of either ATP or L-Glu to the
enzyme increases the binding affinity of the other by 18-fold, whereas
the binding of L-Glu or L-
-aminobutyrate
decreases the binding affinity of the other by 6-fold. Similarly to the
mammalian enzyme, cystamine is a time-dependent, irreversible inhibitor of T. brucei
-GCS. It has been
suggested by several studies that cystamine labels an active site Cys
residue essential for catalysis. Among the enzymes reported to be
inactivated by cystamine, only one Cys residue is invariant (Cys-319 in
T. brucei
-GCS). Mutation of Cys-319 to Ala in T. brucei
-GCS renders the enzyme insensitive to cystamine
inactivation without significantly affecting the enzyme's catalytic
efficiency, kinetic mechanism, or substrate affinities. These studies
suggest that cystamine inactivates the enzyme by blocking substrate
access to the active site and not by labeling an essential active site
residue.
![]()
INTRODUCTION
Top
Abstract
Introduction
Procedures
Results
Discussion
References
-glutamylcysteine synthetase (
-GCS).1 This enzyme
catalyzes the ATP-dependent ligation of L-Cys
and L-Glu to produce
-glutamylcysteine.
-GCS is the
rate-limiting enzyme in the biosynthesis of glutathione in mammalian
cells (2) and of trypanothione in the trypanosomatid, Leishmania
tarentolae (5). An enzyme-activated inhibitor of
-GCS,
buthionine sulfoximine, cures mice infected with T. brucei
(6), implicating
-GCS as a potential drug target. The finding that
trypanosomes lack catalase (7), and consequently possess an
intracellular hydrogen peroxide concentration 100 times that found in
mammalian cells, may account for the selective toxicity of glutathione
depletion on the trypanosome (8). A number of other studies also
demonstrate that oxidative stress has detrimental effects on T. brucei viability. Deletion of even a single allele of
trypanothione reductase in Leishmania donovani decreased
survival in macrophages (9). Lysis of the cattle variant of T. brucei by haptoglobin in human serum is likely to be mediated by
H2O2 (10).
-GCS amplification in L. tarentolae cell lines resistant to antimonials and arsenicals was
an essential factor in the resistant phenotype (5).
-GCS suggest that the reaction proceeds through
the generation of a
-glutamylphosphate intermediate (11). This
result is supported by the finding that buthionine sulfoximine is
phosphorylated by
-GCS in the presence of ATP to form a tight
binding transition state analog (12, 13). Studies to delineate the
kinetic mechanism of mammalian
-GCS have provided conflicting
results; the reaction has been proposed to proceed through an ordered
ter-ter mechanism (11), an ordered A (ATP) random BC mechanism (14,
15), a random AB ordered C (L-Aba) mechanism (16), and
various ping-pong mechanisms (17, 18).
-GCS from any species. Mammalian, worm, and T. brucei
-GCS have been demonstrated to be inactivated by
cystamine (16, 19-21). Inactivation is proposed to proceed through
formation of a disulfide bond to a Cys residue in the active site (19, 22). L-Glu protects the mammalian enzyme from cystamine
inactivation, suggesting the labeled Cys residue may be in the
L-Glu binding site (23). These data have been used to
suggest a role for this Cys residue in catalysis. Several other
inhibitors that inactivate the enzyme are also thought to react to the
same Cys residue (24, 25). Comparison of the amino acid sequences for
the enzymes that have been demonstrated to be inactivated by cystamine
reveals only a single conserved Cys residue, T. brucei
-GCS Cys-319, suggesting this residue is likely to mediate the
response to cystamine. However, the role of this residue in catalysis
is unknown.
-GCS and reported
preliminary enzyme characterization (20). In this paper, we address the kinetic mechanism of
-GCS from T. brucei and characterize
the role of Cys-319 in cystamine inactivation and catalysis. The
T. brucei
-GCS reaction mechanism is best described by a
random ter-reactant mechanism. However, the mechanism also predicts
that the binding affinities of some of the substrates are influenced by
the prior binding of others. Our studies demonstrate that Cys-319 is
the site of cystamine inactivation, but this residue does not play a
significant role in substrate binding or catalysis. These studies
suggest that cystamine inactivates the enzyme by blocking substrate
access to the active site and not by labeling an essential active site
residue.
![]()
EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results
Discussion
References
(Strategene) vector using helper phage R408
(Strategene) and Escherichia coli strain BO265. A 1-kilobase
pair fragment containing the mutation was subcloned to the expression
constructs and verified by DNA sequencing.
-GCS as
an N-terminal His6-tagged fusion protein under control of a
T7 promoter (20). We found better expression levels and greater
purification can be obtained using a C-terminal His8 tag.
The vector was constructed as follows. PCR primers were designed to
insert a NsiI restriction site on the 5' end of the gene and
a TEV protease site followed by a SacII site on the
3' end (sense primer = 5'-AAAATGCATCTTCTAACCACTGGCGGCCAG; antisense primer = 5'-AAACCGCGGGCCCTGAAAATAAGGATTCTCGTCGACCCCTTCGCGTTGTCTTTTACT). These
primers were used to PCR the gene from pTB12.1 (20), and the resulting
PCR fragment was subcloned into the NsiI and
SacII sites of pLOD11 (26). An oligonucleotide linker,
flanked with a SacII site on one side and a
HindIII site on the other (sense oligonucleotide = 5'-GGCATCACCATCACCATCACCATCACTGAA; antisense oligonucleotide = 5'-ACGTTTCAGTGATGGTGATGGTGATGGTGATGCCGC) was next used to place a
His8 tag site at the C terminus of
-GCS to yield the
final expression construct, pTbCtag.
GCS and TbC319A
GCS were expressed and purified from
BL21/DE3 cells as described previously, except the cells were cotransformed with pREP4 (Qiagen) to more tightly regulate the protein
expression. Approximately 10,000 freshly transformed colonies were used
to inoculate 6 liters of LB, which was incubated at 37 °C. Protein
expression was induced when cells reached 1 OD600 by the
addition of isopropyl-
-D-thiogalactopyranoside (0.2 mM) and the temperature was lowered to 27 °C. Cells were
harvested by centrifugation 6-8 h after induction, resuspended, and
lysed in buffer A (50 mM Tris-HCl, pH 8.0, 100 mM NaCl, 5 mM MgCl2, 1 mM
-mercaptoethanol), containing protease inhibitors (2 mM phenylmethylsulfonyl fluoride, 2 µg/ml leupeptin, 4 µg/ml antipain, 20 µg/ml benzamidine, 2 µg/ml pepstatin, 2 µg/ml chymostatin), and 1 mg/ml lysozyme. After centrifugation
(150,000 × g for 1 h at 4 °C), the supernatant
was applied to a Ni2+-agarose column (Qiagen) equilibrated
in buffer A. The column was washed with buffer A containing 0.5 M NaCl, and the His-tagged protein was eluted with a
gradient of imidazole (0-250 mM) in buffer A.
-GCS-containing fractions were dialyzed, concentrated in buffer A
plus 1 mM
-octaglucoside, and applied to a Hi/Load Superdex 200 16/60 gel filtration column (Amersham Pharmacia Biotech) in buffer A. The protein was determined to be greater than 98% pure by
SDS-polyacrylamide gel electrophoresis analysis. The molecular mass of
the purified enzyme is 77 kDa.
-GCS.
-GCS
activity was followed at 37 °C using a spectrophotometric assay,
which couples ADP production to NADH oxidation as described (20). Buffer (100 mM Tris-HCl, pH 8.0, 150 mM KCl, 20 mM MgCl2, 2 mM phosphoenolpyruvate,
0.27 mM NADH) was mixed with type III rabbit muscle
pyruvate kinase (5 units of 350-600 unit/mg of redissolved lyophilized
powder; Sigma), type II rabbit muscle lactic acid dehydrogenase (10 units of 800-1200 unit/mg ammonium sulfate suspension; Sigma), and
-GCS substrates to a final reaction volume of 0.5 ml. The assay was
initiated by the addition of
-GCS. L-
-aminobutyric acid (L-Aba) was used in place of L-Cys unless
specified. For specific activity measurements, the concentrations of
ATP, L-Aba, and L-Glu were 5, 100, and 10 mM, respectively.
-GCS concentration ranged from 0.1 to
0.4 µM. The enzyme concentration was determined by
measuring the OD280. The extinction coefficient for
T. brucei
-GCS was determined to be 1.35 (mg/ml)/OD as
described (27). Briefly, the extinction coefficient for denatured
enzyme was determined based on its primary amino acid sequence by
calculation using the ProtParam tool on the ExPASy web
site.2 The enzyme was
denatured in 6 M guanidinium-HCl, 0.02 M
phosphate, pH 6.5, and the absorbance at 280 nm was determined. Using
the extinction coefficient for the denatured enzyme, the protein
concentration of the sample was determined. This concentration was used
to determine the extinction coefficient of the native enzyme.
-GCS-catalyzed reaction (14). However, we observed no inhibitory
effects of NADH on T. brucei
-GCS in the range of
0.1-0.6 mM NADH. Thus, the concentration of NADH in the
assay mix is not having an inhibitory effect on the enzyme.
GCS and TbC319A
GCS for different times at various
inhibitor concentrations. Aliquots of the reaction were removed and
diluted 1/50 into a standard 0.5-ml reaction mixture, and the remaining activity was measured by the standard assay (above).
-Mercaptoethanol was removed from the enzyme preparation on a
10 × 30-cm Fast desalting column (Sephadex G-25; Amersham
Pharmacia Biotech) prior to these studies. To demonstrate that
cystamine inactivation was irreversible, cystamine-inactivated
wt-Tb
GCS (incubated with 1 mM cystamine for 30 min) was
run on the Fast desalting column to remove excess inhibitor prior to
assay.
GCS and TbC319A
-GCS at a range of substrate concentrations. A complete matrix of rates as a function of substrate concentration (L-Glu, 0.1-8 mM; ATP, 0.04-2 mM;
L-Aba, 2.5-100 mM) were collected such that
for any given concentration of any one substrate the rates were
measured over the entire range of the other two substrates. Curve
fitting and modeling of the kinetic data was based on the rapid
equilibrium rate equations (28) and was performed using Sigma Plot
(SPSS Inc.).
![]()
RESULTS
Top
Abstract
Introduction
Procedures
Results
Discussion
References
-GCS--
Cys-319 in T. brucei
-GCS (Fig.
1) was mutated to Ala and purified as
described under "Experimental Procedures." The purified wild-type
T. brucei
-GCS (wt-Tb
GCS) and the Cys-319 to Ala
mutant enzyme (TbC319A) both have kcat values of
2-3 s
1 in the presence of saturating concentrations of
all three substrates (standard assay conditions described under
"Experimental Procedures"). Thus, mutation of Cys-319 to Ala had no
effect on the catalytic rate of the enzyme under these conditions. The
wild-type enzyme is irreversibly inactivated by cystamine in a
time-dependent reaction. Incubation of the wild-type enzyme
with as little as 10 µM cystamine for 10 min results in
75% loss in enzyme activity (Fig. 2).
The enzyme remains inactivated after removal of free cystamine by chromatography on Sephadex G-25. Similarly to the mammalian enzyme (22), activity is partially restored by addition of a reduced thiol (10 mM dithiothreitol for 10 min). In contrast, TbC391A
-GCS
is completely resistant to cystamine inactivation, and the enzyme
retains full activity even after incubation with 10 mM cystamine for 1 h (Fig. 2).
![]()
View larger version (17K):
[in a new window]
Fig. 1.
Amino acid sequence alignment of
representative
-GCSs in the region of Cys-319. The amino acid
sequences were obtained from the published references: T. brucei (20), rat (33), Saccharomyces cerevisiae (34),
Schizosaccharomyces pombe (35), and Caenorhabditis
elegans (36).

View larger version (18K):
[in a new window]
Fig. 2.
The effects of cystamine on the activity of
wt-Tb
GCS and TbC319A
-GCS. Enzymes were incubated with
cystamine at the depicted concentration for either 10 min or 1 h
before assay. Data are displayed as the percentage of the control
activity (initial velocity with inhibitor/initial velocity without
inhibitor) versus cystamine concentration (mM):
, wt-Tb
GCS, 10-min incubation;
, wt-Tb
GCS, 1-h incubation;
, TbC319A
-GCS, 10-min incubation;
, TbC319A
-GCS, 1-h
incubation.
Kinetic Mechanism of
-GCS--
A matrix of kinetic data was
collected for wt-Tb
GCS and TbC319A
-GCS using a range of
substrate concentrations, such that one substrate was held constant
while the other two were varied. The procedure was repeated until all
combinations of fixed and variable substrates had been collected (Fig.
3). Inspection of the Lineweaver-Burk
plots indicates that the substrates form a ternary complex in the
enzyme active site. A ping-pong mechanism is ruled out because the
Lineweaver-Burk plots for all substrate combinations clearly converge
(Fig. 3). Further variation of L-Glu and ATP in a constant
ratio (1:10) versus varied L-Aba produces a
series of Lineweaver-Burk plots (1/V versus
1/[L-Aba]) that converge (Fig.
4). Similar results were obtained when
varying L-Glu and L-Aba at a constant ratio
(1:20) versus varied ATP (data not shown). These results
demonstrate that a product release step does not occur between the
binding of ATP or L-Glu and L-Aba or between
the binding of L-Glu or L-Aba and ATP (28).
Thus our results are not consistent with the two possible ping-pong
mechanisms in which: 1) ADP is released after phosphorylation of
L-Glu but prior to binding of L-Aba or 2) ADP
is released after generation of a phosphorylated enzyme intermediate
prior to the binding of the other substrates.
|
|
GCS and TbC319A
-GCS were best fit
by the equation below for a rapid equilibrium random ter-reactant system, where Kglu, KAba,
KATP are the equilibrium dissociation constants
(Kd values) for the binding of substrate with free
E, and
,
, and
are the interaction factors by
which the dissociation constants of one substrate are influenced by the prior binding of one of the other substrates (Fig.
5). None of the other tested models
provided a satisfactory fit to the data.
|
(Eq. 1) |
|
GCS
fit to Equation 1 are displayed in Fig. 3, and the model derived
parameters are reported in Table I. The
kinetic constants derived from the random ter-reactant model are very
similar for wt-Tb
GCS and TbC319A
-GCS (Table I). The specific
activity (Vmax) is identical for the two
enzymes, and no significant change is observed in the substrate
dissociation constants as a result of the mutation. For both
wt-Tb
GCS and TbC319A
-GCS, there is positive cooperatively
between the binding sites of L-Glu and ATP (
= 0.06 for
wt-Tb
GCS and 0.04 for TbC319A
-GCS). Therefore, the prior binding
of ATP or L-Glu to the enzyme increases the binding
affinity of the enzyme for the other substrate by 18-fold for the
wild-type enzyme and by 23-fold for the mutant enzyme. In contrast,
there is negative cooperatively between the binding sites of
L-Glu and L-Aba (
= 6.3 for wt-Tb
GCS and
5.0 for TbC319A); thus, the binding of one decreases the binding
affinity of the other by 6.3-fold to the wild-type enzyme and by
5.0-fold to the mutant enzyme. ATP and L-Aba do not
significantly effect the binding energies of each other, for either
enzyme (
= 1).
|
|
GCS that the apparent
Km values for L-Glu, L-Aba,
and ATP were 0.24, 10, and 0.07 mM, respectively (20).
These values were obtained by varying the concentration of one
substrate, while holding the concentrations of the other two substrates
at saturating levels. Given the random mechanism for catalysis by
Tb
GCS, the Kmapp values
describe the interaction of a given substrate to enzyme which is bound
to the other two substrates. In contrast, Kglu, KAba, and KATP are the
model derived dissociation constants for the binding of each substrate
to free enzyme. Because the prior binding of some substrates influences
the binding affinity of others, the
Kmapp values will not equal the
model derived dissociation constants but will instead be best
approximated by a combination of the Kd and the
binding interaction factors (e.g.
Kmapp for L-Glu
describes the binding of L-Glu to E*Aba*ATP and
should be similar to the model derived constant

KGlu (Fig. 5)). The model derived
parameters 
KGlu,

KAba, and

KATP (Table I) are within the experimental
errors of the reported Kmapp
values, providing good agreement between the data.
| |
DISCUSSION |
|---|
|
|
|---|
Few studies have shed understanding on the nature of the
-GCS
active site.
-GCS from several species, including T. brucei, is inactivated by cystamine. Prior studies on the
mammalian enzyme suggested that the inactivation occurred by labeling
of a Cys residue (19, 22). This residue was believed to be in the
L-Glu binding site because L-Glu protects
against inactivation, suggesting that the labeled Cys residue might be
important for catalysis (23). A single Cys residue (Cys-319) is
conserved among those enzymes reported to be sensitive to cystamine
(Fig. 1). Mutagenesis of Cys-319 to Ala in T. brucei
-GCS
renders the enzyme resistant to cystamine inactivation, demonstrating
that Cys-319 is the site of cystamine labeling in the wild-type enzyme.
However, mutation of Cys-319 has no significant effect on the specific
activity of the enzyme, on the reaction mechanism or on the substrate
binding parameters. Thus, clearly Cys-319 does not play a significant role in catalysis or substrate binding. Instead, these data suggest that cystamine inactivates the enzyme by blocking access of substrates to the active site. The amino acid sequence of
-GCS from L. donovani was recently reported, and it lacks Cys-319 (5). These
data suggest that the L. donovani enzyme will be resistant
to cystamine inactivation.
The full kinetic profile of the Tb
-GCS was obtained to determine the
kinetic mechanism of the enzyme. The kinetic data collected for both
wild-type and TbC319A T. brucei
-GCS are best fit to the
equation that describes a rapid equilibrium random ter-reactant mechanism in which significant dependences exist between the binding of
some of the substrate pairs. There is a favorable interaction energy of
1.7 kcal/mol (
G interaction =
RTln
K(Glu or
ATP)/K(Glu or ATP)) between the
L-Glu and ATP binding sites, an unfavorable interaction energy of 1.1 kcal/mol between the L-Glu and
L-Aba binding sites, and no interaction between the ATP and
L-Aba binding sites. These results are consistent with what
is known about the reaction mechanism. ATP transfers the
-phosphate
to L-Glu, and the activated L-Glu undergoes
nucleophilic attack by the amino group of L-Aba (11). Thus,
uniquely the L-Glu binding site must be positioned so that L-Glu can interact with both the other substrates, while
ATP and L-Aba would not require direct interaction. It has
been reported that low levels of ATP hydrolysis (<1% of the overall
reaction) occurs in the absence of the other substrates and that
L-Glu inhibits this reaction (29). The cooperativity
between the L-Glu and ATP binding sites might be expected
to reduce the extent of this unwanted side reaction.
Several possible kinetic mechanisms have been proposed for mammalian
-GCS, including partially ordered ter-reactant (14-16) and
ping-pong mechanisms (17, 18). Our data are not consistent with a
ping-pong mechanism and supports the hypothesis that the substrates
form a ternary complex on the enzyme prior to catalysis. In contrast to
these other studies, our data clearly support a random mechanism for
-GCS catalysis. However, because the substrates exhibit dependences
on each other for binding, in the absence of the modern robust fitting
techniques that allow the entire data set to be fit to the model
simultaneously, this mechanism would be difficult to distinguish from
the previously proposed partially ordered mechanisms (e.g.
ordered A, random BC (14, 15), or random AB, ordered C (16)). T. brucei
-GCS could also exhibit species differences compared
with mammalian
-GCS, but we find that the recombinant human
-GCS
also follows a rapid equilibrium random
mechanism.3 T. brucei glutathionylspermidine synthetase, which catalyzes a
similar reaction to
-GCS, has also been reported to follow a rapid
equilibrium random mechanism (30). These data suggest that a random
kinetic pattern is common among ATP-dependent peptide ligases.
The model for the kinetic mechanism of
-GCS reported in this paper
provides a method to assess effects of mutations on the reaction as we
have done for the TbC319A
-GCS mutant. In addition, the activity of
mammalian
-GCS has been reported to be influenced by interaction
with a regulatory subunit (31, 32). The regulatory subunit decreases
the apparent Km for L-Glu, but its effects on the reaction mechanism have not yet been addressed. A
regulatory subunit has not yet been found associated with any of the
non-mammalian enzymes, leaving open the possibility that differences in
reaction mechanism may be present between the regulated mammalian
enzyme and T. brucei
-GCS. In the future,
characterization of differences between these two enzyme will aid in
the design of species-selective T. brucei inhibitors.
| |
FOOTNOTES |
|---|
* This work was supported by grants from the National Institutes of Health (R01 AI34432) and the Buroughs Wellcome Foundation (to M.A.P.) and by a National Institutes of Health Predoctoral Fellowship T32 GM07062 (to D. L. B.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Cell Regulation Graduate Program.
§ To whom correspondence should be addressed: Dept. of Pharmacology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75235-9041. Tel.: 214-648-3637; Fax: 214- 648-3811.
The abbreviations used are:
-GCS,
-glutamylcysteine synthetase; wt-Tb
GCS, wild-type T. brucei
-GCSTbC319A, Cys-319 to Ala mutant T. brucei
-GCSL-Aba, L-
-aminobutyratePCR, polymerase chain reaction.
2 ProtParam is available via the World Wide Web (http://www.hcuge.ch).
3 D. L. Brekken and M. A. Phillips, unpublished observation.
| |
REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
B. E. Janowiak and O. W. Griffith Glutathione Synthesis in Streptococcus agalactiae: ONE PROTEIN ACCOUNTS FOR {gamma}-GLUTAMYLCYSTEINE SYNTHETASE AND GLUTATHIONE SYNTHETASE ACTIVITIES J. Biol. Chem., March 25, 2005; 280(12): 11829 - 11839. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Jez and R. E. Cahoon Kinetic Mechanism of Glutathione Synthetase from Arabidopsis thaliana J. Biol. Chem., October 8, 2004; 279(41): 42726 - 42731. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Jez, R. E. Cahoon, and S. Chen Arabidopsis thaliana Glutamate-Cysteine Ligase: FUNCTIONAL PROPERTIES, KINETIC MECHANISM, AND REGULATION OF ACTIVITY J. Biol. Chem., August 6, 2004; 279(32): 33463 - 33470. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Fraser, P. Kansagra, C. Kotecki, R. D. C. Saunders, and L. I. McLellan The Modifier Subunit of Drosophila Glutamate-Cysteine Ligase Regulates Catalytic Activity by Covalent and Noncovalent Interactions and Influences Glutathione Homeostasis in Vivo J. Biol. Chem., November 21, 2003; 278(47): 46369 - 46377. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. T. Huynh, V. T. Huynh, M. A. Harmon, and M. A. Phillips Gene Knockdown of {gamma}-Glutamylcysteine Synthetase by RNAi in the Parasitic Protozoa Trypanosoma brucei Demonstrates That It Is an Essential Enzyme J. Biol. Chem., October 10, 2003; 278(41): 39794 - 39800. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Hamilton, J. H. Wu, M. Alaoui-Jamali, and G. Batist A novel missense mutation in the {gamma}-glutamylcysteine synthetase catalytic subunit gene causes both decreased enzymatic activity and glutathione production Blood, July 15, 2003; 102(2): 725 - 730. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Abbott, J. Pei, J. L. Ford, Y. Qi, V. N. Grishin, L. A. Pitcher, M. A. Phillips, and N. V. Grishin Structure Prediction and Active Site Analysis of the Metal Binding Determinants in gamma -Glutamylcysteine Synthetase J. Biol. Chem., November 2, 2001; 276(45): 42099 - 42107. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Fraser, R. D. C. Saunders, and L. I. McLellan Drosophila melanogaster Glutamate-Cysteine Ligase Activity Is Regulated by a Modifier Subunit with a Mechanism of Action Similar to That of the Mammalian Form J. Biol. Chem., January 4, 2002; 277(2): 1158 - 1165. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||